Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Supasa, Piyada; Zhou, Daming; Dejnirattisai, Wanwisa; Liu, Chang; J. Mentzer, Alexander; M. Ginn, Helen; Zhao, Yuguang; M. E. Duyvesteyn, Helen; Nutalai, Rungtiwa; Tuekprakhon, Aekkachai; Wang, Beibei; C. Paesen, Guido; Slon-Campos, Jose; López‐Camacho, César; Hallis, Bassam; S. Coombes, Naomi; R. Bewley, Kevin; Charlton, Sue; S. Walter, Thomas; Barnes, Eleanor; Dunachie, Susanna; Skelly, Donal; Lumley, Sheila; Baker, Natalie; Shaik, Imam; E. Humphries, Holly; Godwin, Kerry; Gent, Nick; Sienkiewicz, Alex; Dold, Christina; H. Levin, Robert; Dong, Tao; J. Pollard, Andrew; C. Knight, Julian; Klenerman, Paul; W. Crook, Derrick; Lambe, Teresa; Clutterbuck, Elizabeth; Bibi, Sagida; Flaxman, Amy; Bittaye, Mustapha; Belij‐Rammerstorfer, Sandra; C. Gilbert, Sarah; R. Hall, David; A. Williams, Mark; G. Paterson, Neil; James, William; W. Carroll, Miles; E. Fry, Elizabeth; Mongkolsapaya, Juthathip; Ren, Jingshan; I. Stuart, David; Screaton, Gavin

doi:10.1016/j.cell.2021.02.033

Public

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Published in Cell • Feb 18, 2021

Authors:

Piyada Supasa

Daming Zhou

Wanwisa Dejnirattisai

Abstract

SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibo...

Subject

Neutralization

Virology

Biology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!